Table 3 Blood Product Utilization
From: Retrospective study assessing outcomes in cardiac surgery after implementation of Quantra
Pre-Quantra | Post-Quantra | P Value | |
|---|---|---|---|
A. Blood products administered (mean units, range) | |||
pRBC | 0.453 (0, 5) | 0.406 (0, 6) | 0.8027 |
FFP | 0.547 (0, 6) | 0.016 (0, 1) | 0.0004* |
Platelets | 0.359 (0, 4) | 0.266 (0, 2) | 0.4879 |
Cryoprecipitate | 0.141 (0, 5) | 0.0467 (0, 1) | 0.3134 |
Total, all products | 1.50 (0, 19) | 0.734 (0, 7) | 0.0933 |
B. Patients receiving blood products (N, %) | |||
pRBC | 13 (20.3) | 13 (20.3) | 1.00 |
FFP | 14 (21.9) | 1 (1.6) | 0.0004* |
Platelets | 10 (15.6) | 12 (18.8) | 0.6394 |
Cryoprecipitate | 3 (4.7) | 3 (4.7) | 1.00 |
Total, any product | 22 (34.4) | 19 (29.7) | 0.5689 |